NEW Bladder Cancer Clinical Trial – MK3475-057 Keynote Study

Date: 13 August, 2019

Bladder Cancer – MK3475-057 Study (Clinical Trial):

The MK-3475-057 study is a Phase II Clinical Trial for Bladder Cancer. This trial targets patients with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy. 

Eligible patients must have first received an adequate course of BCG therapy. This defined as, at least 5 instillations of induction BCG and an overall of at least 7 instillations of BCG within 9 months.

For patients to be unresponsive to BCG, they must have persistent high risk NMIBC at 6 months (±4 weeks) after adequate BCG or recurrent high risk NMIBC within 9 months of the last BCG instillation despite having received adequate BCG.

Furthermore, an eligible patient’s most recent cystoscopy must have High Grade Ta or any Grade T1 without CIS. 

https://clinicaltrials.gov/ct2/show/NCT02625961?term=MK-3475-057&rank=1